Comparative Pharmacology
Head-to-head clinical analysis: HEMANGEOL versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEMANGEOL versus INDERIDE LA 120 50.
HEMANGEOL vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hemangeol (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors. In infantile hemangioma, the exact mechanism is not fully understood, but proposed actions include vasoconstriction, inhibition of angiogenesis by downregulating VEGF and bFGF, and induction of apoptosis in endothelial cells.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
3 mg/kg/day orally divided into 2 doses for pediatric patients; adult use not indicated
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
3-4 hours in infants (0-1 year) and 3.5-4.5 hours in children (1-6 years); clinical context: requires TID dosing to maintain therapeutic effect.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Primarily hepatic metabolism via UGT1A9 and CYP2C9; <5% excreted unchanged in urine. Biliary/fecal elimination of metabolites; exact % not defined.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category C
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination